Sandesh Mahatme, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The filing, submitted on Form 3, indicates Mahatme's beneficial ownership of non-derivative securities, specifically 26,000 common shares of CRISPR Therapeutics, which are subject to a stock option right to buy at a price of $44.81 per share. The option was granted on October 16, 2023, and is set to vest over 36 months, with the first installment vesting on November 16, 2023. The form was filed as a single reporting person and included a Power of Attorney signed by Sandesh Mahatme.

Sandesh Mahatme, a director and 10% owner of CRISPR Therapeutics, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on May 30, 2024. The filing, submitted on Form 3, indicates Mahatme's beneficial ownership of non-derivative securities, specifically 26,000 common shares of CRISPR Therapeutics, which are subject to a stock option right to buy at a price of $44.81 per share. The option was granted on October 16, 2023, and is set to vest over 36 months, with the first installment vesting on November 16, 2023. The form was filed as a single reporting person and included a Power of Attorney signed by Sandesh Mahatme.